Dedicated to changing lives by developing novel RNA therapies for people living with severe genetic rare diseases that currently have no treatment options.
Location: Netherlands, South Holland, Leiden
Employees: 51-200
Phone: +31 88 166 7000
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Foresite C... | foresiteca... |
| - | Gilde Heal... | gildehealt... |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 12
| Date | Title | Description | Source |
| 13.03.2024 | ProQR Announces Year End 2023 Operating and Financial Result... | - | globenewsw... |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look li... | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past... | businessin... |
| 04.11.2021 | ProQR Announces Third Quarter 2021 Operating and Financial R... | Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 antici... | marketscre... |
| 17.06.2021 | PROQR THERAPEUTICS N.V. ProQR Therapeutics N : Plain-langua... | This plain-language summary (or PLS) describes a paper on Leber congenital amaurosis 10 that was pub... | marketscre... |
| 06.05.2021 | PROQR THERAPEUTICS N.V. ProQR Announces First Quarter 2021 ... | Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data an... | marketscre... |
| 24.03.2021 | ProQR’s RNA therapy on track to pivotal tests in rare, inher... | Netherlands-based ProQR is developing its experimental therapy, QR-421a, as a treatment for Usher sy... | medcitynew... |
| 31.03.2020 | Myovant grabs $40M upfront in regional deal for relug... | → Having just filed for the European approval of its uterine fibroids drug relugolix, Myov... | endpts.com... |
| 14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey ... | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Ther... | endpts.com... |
| 13.09.2017 | ProQR spins out CNS assets to form RNA rare disease biotech | ProQR has spun out its CNS assets to form Amylon Therapeutics. The offshoot starts life with seed fu... | fiercebiot... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
Show more